In the spring of 2014, a small Michigan biotech closed a $6.5 million deal to buy several cell therapies from the French drug giant Sanofi. They included a technology to treat weekend warriors with worn-out knees and a new kind of skin graft for people with catastrophic burns. Almost exactly five years later, the acquisitions […]

Cambridge-based cell therapy firm Vericel Corp. has forged a $142 million deal to license a gel used to help heal burns that made just over $3 million in sales last year at an Israeli company. Vericel (Nasdaq: VCEL) will pay $17.5 million upfront and up to $125 million in milestones to license and sell the burn repair product NexoBrid […]